Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 4
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Resolution Potential of Necrotic Cell Death Pathways.
Mázló A, Tang Y, Jenei V, Brauman J, Yousef H, Bácsi A, Koncz G. Mázló A, et al. Int J Mol Sci. 2022 Dec 20;24(1):16. doi: 10.3390/ijms24010016. Int J Mol Sci. 2022. PMID: 36613458 Free PMC article. Review.
EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.
Cserepes M, Nelhűbel GA, Meilinger-Dobra M, Herczeg A, Türk D, Hegedűs Z, Svajda L, Rásó E, Ladányi A, Csikó KG, Kenessey I, Szöőr Á, Vereb G, Remenár É, Tóvári J. Cserepes M, et al. Cancers (Basel). 2022 May 13;14(10):2407. doi: 10.3390/cancers14102407. Cancers (Basel). 2022. PMID: 35626010 Free PMC article.
Patients with recurrent/metastatic disease undergo combination chemotherapy containing cetuximab, the monoclonal antibody used against the epidermal growth factor receptor (EGFR). Cetuximab augments the effect of chemotherapy; however, a significant number of patients show …
Patients with recurrent/metastatic disease undergo combination chemotherapy containing cetuximab, the monoclonal antibody used against the e …
Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients.
Fagyas M, Bánhegyi V, Úri K, Enyedi A, Lizanecz E, Mányiné IS, Mártha L, Fülöp GÁ, Radovits T, Pólos M, Merkely B, Kovács Á, Szilvássy Z, Ungvári Z, Édes I, Csanádi Z, Boczán J, Takács I, Szabó G, Balla J, Balla G, Seferovic P, Papp Z, Tóth A. Fagyas M, et al. Geroscience. 2021 Oct;43(5):2289-2304. doi: 10.1007/s11357-021-00467-2. Epub 2021 Oct 21. Geroscience. 2021. PMID: 34674152 Free PMC article.
Type I Interferon Production of Plasmacytoid Dendritic Cells under Control.
Bencze D, Fekete T, Pázmándi K. Bencze D, et al. Int J Mol Sci. 2021 Apr 18;22(8):4190. doi: 10.3390/ijms22084190. Int J Mol Sci. 2021. PMID: 33919546 Free PMC article. Review.
Deficiency in type I IFN production increases the risk of more severe viral infections and the development of certain allergic reactions, and supports tumor resistance; nevertheless, its overproduction promotes autoimmune reactions. ...
Deficiency in type I IFN production increases the risk of more severe viral infections and the development of certain allergic reacti …
Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes.
Orosz ZZ, Bárdos H, Shemirani AH, Beke Debreceni I, Lassila R, Riikonen AS, Kremer Hovinga JA, Seiler TG, van Dorland HA, Schroeder V, Boda Z, Nemes L, Früh Eppstein B, Nagy B, Facskó A, Kappelmayer J, Muszbek L. Orosz ZZ, et al. Int J Mol Sci. 2019 Nov 27;20(23):5963. doi: 10.3390/ijms20235963. Int J Mol Sci. 2019. PMID: 31783511 Free PMC article.